Navigation Links
MPM Capital Leads Investment in Proteon Therapeutics
Date:3/5/2009

Dr. Steven St. Peter Named to Proteon Board of Directors

KANSAS CITY, Mo., March 5 /PRNewswire/ -- MPM Capital, one of the world's largest life sciences-dedicated venture capital investors, announced today that it is the lead investor in a $38 million Series B equity financing of Proteon Therapeutics. In addition, Dr. Steven St. Peter, Managing Director of MPM Capital, has been named to the Proteon Therapeutics Board of Directors.

Proteon recently initiated a Phase 1/2 clinical trial of its lead product, PRT-201. PRT-201 is a recombinant human elastase that is being studied for its ability to improve arteriovenous fistula (AVF) surgery outcomes in patients requiring chronic hemodialysis.

"MPM continues to be very impressed with Proteon and the progress that the company has made," said Dr. Steven St. Peter. "In addition, this marks the first investment by MPM in a company with a substantial Kansas City presence. We have long followed the positive developments in the Kansas City area life sciences sector, and this investment affirms our view that attractive opportunities originate there."

Over the last several years, Dr. Steven St. Peter has worked informally with the Kansas City Area Life Sciences Institute in an advisory capacity. In addition, he currently serves as a member of the Kansas Bioscience Authority's Heartland BioVentures Advisory Board. Originally from Wichita, Dr. St. Peter has a B.A. in Chemistry from the University of Kansas. He completed his Doctor of Medicine at Washington University in St. Louis and his residency and fellowship at the Hospital of the University of Pennsylvania.

"Proteon is very pleased to have attracted the interest of MPM Capital, one of the world's premier healthcare venture capital firms," said F. Nicholas Franano, M.D., Chief Scientific Officer and founder of Proteon Therapeutics. "MPM's understanding of the life sciences industry makes them an ideal investor. In addition, I have known and worked with Steven St. Peter for over 20 years and am excited about the contribution he will make to our board of directors and the future direction of our company."

In addition to MPM Capital, the other new investor in this round of financing is the Vectis Healthcare & Life Sciences Fund. MPM and Vectis have a strong and deep relationship.

Tim Noyes, CEO of Proteon, said, "Proteon welcomes these additions to our already strong investor base. This financing will allow us to fund very significant clinical development in a field that needs better solutions."

About MPM Capital

MPM Capital is one of the world's largest dedicated investors in the life sciences. With offices in Boston and San Francisco, the firm manages committed capital in excess of $2 billion. MPM Capital has a deep and experienced team capable of investing from early-stage to late-stage which positions it to invest across the full spectrum of healthcare innovation. For additional information, visit www.mpmcapital.com

About Proteon Therapeutics

Proteon Therapeutics, Inc. is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company is headquartered in Waltham, Mass., and has research facilities in Kansas City, Mo. For additional information, visit www.proteontherapeutics.com


'/>"/>
SOURCE MPM Capital
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. AtriCure to Present at Roth Capital Partners 2007 New York Conference
3. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
4. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
5. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
6. iCAD to Present at Americas Growth Capital 4th Annual Emerging Growth Conference
7. Pharsight Files Application for Nasdaq Capital Market Listing
8. Advanced Life Sciences Joins NASDAQ Capital Market
9. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
10. Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds
11. Caxton-Iseman Capital Acquires Conney Safety Products, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
(Date:10/12/2017)... RAPIDS, Mich. (PRWEB) , ... October 12, 2017 ... ... Wellness, has been named one of Michigan’s 2017 Best and Brightest in Wellness® ... and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. ...
(Date:10/12/2017)... BALTIMORE (PRWEB) , ... October 12, 2017 , ... ... average of $3,296 in property taxes a year. In some states—like New York, ... higher. , By contrast, many overseas retirement havens have extremely low property-tax rates, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... University of California Berkeley, and other leading institutions in announcing the launch of ... institutions to change the way animals are raised for food. , Founding members ...
(Date:10/12/2017)... ... October 12, 2017 , ... Nvision Biomedical Technologies ... with the addition of industry sales leader, Thomas (Tom) Slott, as Senior Vice ... distribution and sales network, direct the efforts of the surgical sales teams, manage ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
Breaking Medicine Technology: